



# From Curiosity to Discovery

International Research & Development Press Conference

## Speaker Biography



**Michael Mark, Ph.D.**  
**Vice President of Metabolic Diseases, Boehringer Ingelheim**

Michael Mark is the Vice President Metabolic Diseases Research at Boehringer Ingelheim based in Biberach, Germany. He leads the research department and is responsible for all discovery activities in Metabolic Diseases. Together with his team, Dr. Mark has developed a competitive portfolio with various preclinical and several clinical development projects currently ongoing, amongst them, DPP-4 inhibitors as well as SGLT2 inhibitors.

Michael Mark has served more than 20 years in the pharmaceutical industry and has authored many peer-reviewed publications and various book chapters. In addition he has contributed to numerous patents. He was involved in the discovery and development of repaglinide, (Prandin<sup>®</sup>), a non-sulfonylurea insulin secretagogue.

Educated as a pharmacist, Michael Mark holds a Ph.D. degree in Pharmacology from the University of Tuebingen, Germany.